ST
STRO.US Sutro Biopharma
- Market cap
- USD 148M
- P/E
- -
- P/B
- 2.11x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is STRO.US undervalued?
Graham numberThe Graham number of Sutro Biopharma cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sutro Biopharma fundamental analysis
No fundamental analysis for Sutro Biopharma yet.
Sutro Biopharma stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sutro Biopharma
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carci…
Full company profileSutro Biopharma financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sutro Biopharma annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 59.7M | 51.7M | 38.4M | 42.7M | 42.7M | 61.9M | 67.8M | 154M | 62.0M | 102M | 44.6M |
| Gross Profit | 16.2M | -156K | -15.8M | 42.7M | -34.2M | 52.1M | 59.5M | 147M | 54.8M | 95.2M | 41.3M |
| Operating Income | 1.36M | -19.3M | -37.2M | -55.5M | -71.1M | -98.5M | -129M | -89.3M | -238M | -105M | -109M |
| EBITDA | 7.36M | -14.1M | -32.8M | -46.6M | -23.8M | -97.6M | -108M | -67.9M | -180M | -146M | -100M |
| Net Income | 1.70M | -19.7M | -35.3M | -55.7M | -32.1M | -106M | -119M | -107M | -227M | -191M | -145M |
| EPS | 39 | -2.81 | -15 | -24 | -0.99 | -23 | -23 | -18 | -30 | -22 | -8.72 |
| Balance Sheet | |||||||||||
| Total Assets | 69.3M | 40.8M | 223M | 156M | 394M | 341M | 407M | 471M | 387M | 174M | 177M |
| Total Liabilities | 160M | 150M | 91.6M | 58.6M | 62.1M | 88.8M | 190M | 321M | 343M | 306M | 309M |
| Shareholders' Equity | -90.9M | -109M | 132M | 97.8M | 332M | 253M | 217M | 150M | 44.6M | -132M | -133M |
| Cash & Short-term Investments | 47.5M | 22.0M | 204M | 118M | 368M | 198M | 334M | 376M | 317M | 141M | 142M |
| Total Debt | 1.19M | 16.3M | 14.7M | 9.88M | 33.4M | 57.4M | 55.0M | 33.6M | 23.2M | 15.7M | 259M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -13.2M | -37.1M | 12.7M | -65.0M | -67.8M | -81.7M | 3.55M | -112M | -192M | -177M | -137M |
| Capital Expenditure | 4.39M | 3.32M | 1.56M | 3.48M | 7.13M | 15.3M | 7.86M | 4.32M | 3.10M | 1.70M | 191K |
| Free Cash Flow | -17.5M | -40.4M | 11.1M | -68.5M | -74.9M | -97.0M | -4.31M | -116M | -195M | -179M | -138M |
| Ratios | |||||||||||
| ROE | - | - | -26.8% | -57.0% | -9.7% | -41.8% | -54.9% | -71.4% | -510.0% | - | - |
| ROA | 2.5% | -48.3% | -15.8% | -35.6% | -8.2% | -30.9% | -29.3% | -22.7% | -58.7% | -109.9% | -81.9% |
| Net Profit Margin | 2.8% | -38.1% | -91.9% | -130.4% | -75.2% | -170.6% | -175.9% | -69.5% | -366.6% | -186.5% | -324.3% |
| Debt to Equity | - | - | 0.11x | 0.10x | 0.10x | 0.23x | 0.25x | 0.22x | 0.52x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sutro Biopharma dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 463K | 0.09 | - |
| 2021 | - | - | - |
| 2020 | USD 314K | 0.01 | - |
| 2019 | USD 297K | 0.13 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Dec 3, 2025.
Who owns Sutro Biopharma
- Insiders 2.26%
- Institutions 97.75%
- Public & others 0.00%
- Shares outstanding 16.6M
- Free float 9.95M
Top funds holding STRO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Eventide Healthcare & Life Sciences I | 585K | 3.53% | -18.18% | Jun 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 502K | 3.02% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 369K | 2.23% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 175K | 1.05% | +0.51% | Aug 2026 |
| Fidelity Enhanced Small Cap Core ETF | 163K | 0.98% | +0.27% | Oct 2026 |
| iShares Russell 2000 Value ETF | 114K | 0.69% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 ETF | 83.2K | 0.50% | -9.21% | Sep 2026 |
| Vanguard US Momentum Factor ETF | 81.8K | 0.49% | 0.00% | Sep 2026 |
| Goldman Sachs Small Cap Eq Insghts Instl | 77.2K | 0.47% | 0.00% | Jul 2026 |
| GS US Sm Cp CORE Eq Base Inc USD Snap | 68.7K | 0.41% | +1.10% | Aug 2026 |
| Fidelity Extended Market Index | 68.4K | 0.41% | +16.05% | Sep 2026 |
| Goldman Sachs Small Cp Val Insghts Instl | 66.5K | 0.40% | 0.00% | Jul 2026 |
| JPMorgan US Small Company L | 61.7K | 0.37% | 0.00% | Sep 2026 |
| Vanguard Health Care ETF | 45.6K | 0.27% | +0.11% | Sep 2026 |
| iShares Micro-Cap ETF | 43.2K | 0.26% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 34.9K | 0.21% | -9.79% | Sep 2026 |
| Mackenzie GQE US Small Cap F8 | 33.2K | 0.20% | 0.00% | Aug 2026 |
| iShares Core S&P Total US Stock Mkt ETF | 29.6K | 0.18% | +0.03% | Oct 2026 |
| Invesco Russell 2000® Dynamic Mltfct ETF | 29.5K | 0.18% | 0.00% | Oct 2026 |
| Vanguard Explorer Inv | 28.5K | 0.17% | 0.00% | Sep 2026 |
Top institutions holding STRO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Perceptive Advisors LLC | 1.30M | 7.86% | +82.42% | Jun 2026 |
| Bvf Inc | 1.25M | 7.54% | 0.00% | Jun 2026 |
| Affinity Asset Advisors, LLC | 1.17M | 7.06% | +9.63% | Jun 2026 |
| BlackRock Inc | 1.12M | 6.76% | +382.48% | Jun 2026 |
| Samsara BioCapital, LLC | 1.06M | 6.40% | 0.00% | Jun 2026 |
| Kynam Capital Management, LP | 873K | 5.26% | 0.00% | Jun 2026 |
| Orbimed Advisors LLC | 744K | 4.48% | -7.14% | Jun 2026 |
| Balyasny Asset Management LLC | 711K | 4.28% | +52.68% | Jun 2026 |
| Vanguard Capital Management, LLC | 694K | 4.18% | -3.64% | Jun 2026 |
| Eventide Asset Management, LLC | 585K | 3.53% | -18.18% | Jun 2026 |
| Acadian Asset Management LLC | 558K | 3.36% | +49.23% | Sep 2026 |
| Velan Capital Investment Management LP | 512K | 3.09% | 0.00% | Jun 2026 |
| Woodline Partners LP | 458K | 2.76% | +0.13% | Jun 2026 |
| ADAR1 Capital Management LLC | 404K | 2.43% | -22.96% | Jun 2026 |
| Geode Capital Management, LLC | 390K | 2.35% | +127.38% | Jun 2026 |
| Millennium Management LLC | 366K | 2.20% | +73.96% | Jun 2026 |
| State Street Corp | 306K | 1.84% | +487.09% | Jun 2026 |
| Merck & Co Inc | 272K | 1.64% | 0.00% | Jun 2026 |
| Longwood Capital Partners LLC | 270K | 1.63% | +0.31% | Jun 2026 |
| Ameriprise Financial Inc | 245K | 1.47% | 0.00% | Jun 2026 |
Sutro Biopharma company profile
- Company name
- Sutro Biopharma
- Ticker
- STRO.US
- Exchange
- USA Stocks
- Listed since
- Sep 27, 2018
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 129
- Fiscal year end
- December
- Address
- 111 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
- Phone
- 650 881 6500
- Website
- sutrobio.com
About Sutro Biopharma
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Sutro Biopharma management
9- Ms. Jane Chung R.Ph.CEO & Director · born 1971
- Mr. Gregory K. Chow BA, CPA, MBAChief Financial Officer · born 1973
- Dr. Hans-Peter Gerber Ph.D.Chief Scientific Officer · born 1964
- Dr. James R. Swartz DSc, Ph.D., Sc.D.Founder
- Mr. Devendra LuharSenior Vice President of Technical Operations
- Ms. Kari E. LeetchSenior VP and Head of People & Culture
- Mr. Jonathan Fawcett DPHIL, MBBSVP & Head of Clinical Development
- Mr. Lucas DonigianSenior Vice President of Business Development
- Ms. Regina ChengVice President & Controller